Physician profile
Patrick V Hickle
NPI 1346218609
$5,177.13
in general payments reported to CMS, 2019-2025
25 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2023: $2,201 · 2024: $1,344 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867 · Travel and Lodging: $984 · Consulting Fee: $33.92 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.61 |
| Travel and Lodging | $983.64 |
| Consulting Fee | $33.92 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,844.75 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $591.85 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $491.45 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $451.18 | 2019-2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Watchman |
| Atricure, INC. | $303.12 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| E.R. Squibb & Sons, L.L.C. | $186.20 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $172.33 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $172.19 | 2019-2025 | Repatha, Repatha |
| Cvrx, INC. | $147.90 | 2023-2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $122.36 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.58 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $106.07 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $68.10 | 2019-2024 | Opsumit |
| Medicomp INC | $54.41 | 2025 | Telepatch Cardiac Monitor |
| Merck Sharp & Dohme LLC | $52.71 | 2023-2024 | Verquvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $47.74 | 2023 | Cleerly Labs |
| Bayer Healthcare Pharmaceuticals INC. | $46.71 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $35.92 | 2024 | |
| Daiichi Sankyo INC. | $35.85 | 2023 | Injectafer |
| Pfizer INC. | $30.64 | 2023-2024 | |
| Medtronic, INC. | $28.18 | 2024 | Micra |
| Abbott Laboratories | $24.21 | 2025 | Mitraclip |
| Irhythm Technologies, INC. | $20.10 | 2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $17.80 | 2019 | |
| Esperion Therapeutics, INC. | $13.78 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hickle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.